Contract Research, Development, and Manufacturing Organization (CRDMO) Market Size, Share & Industry Analysis, By Service (CMO [API Manufacturing, Finished Product Manufacturing {Solid Dosage Forms, Injectables, and Others}, and Packaging] and CRO [Early Phase Development Services {Chemistry, Manufacturing, and Controls (CMC), Preclinical Service, and Discovery}, Clinical {Phase 1, Phase 2, Phase 3, and Phase 4}, Laboratory Service, and Others]), and Regional Forecast, 2026-2034

The global contract research, development, and manufacturing organization (CRDMO) market size was valued at USD 260.51 billion in 2025. The market is projected to grow from USD 281.16 billion in 2026 to USD 540.51 billion by 2034, exhibiting a CAGR of 8.5% during the forecast period.

Contract research, development, and manufacturing organization (CRDMO) is an end-to-end outsourcing partner in the pharmaceutical and biotechnology industries that combines the research capabilities of a CRO with the development and manufacturing scale of a CMO under one roof. The market growth is attributed to increasing partnerships between pharmaceutical & biotechnology companies and service providers for outsourcing development, manufacturing, and research for their drugs.

Key market players include WuXi AppTec, Pharmaron, and Curia Global, which are focusing on service expansion and facility launches to gain significant market share.

CONTRACT RESEARCH, DEVELOPMENT, AND MANUFACTURING ORGANIZATION (CRDMO) MARKET TRENDS

Growing Mergers and Acquisitions among CRDMOs are identified as a Key Market Trend

Currently, the market for contract research, development, and manufacturing organizations (CRDMOs) is fragmented. Pharmaceutical companies are largely focusing on rapid innovation to improve drug development and manufacturing processes. Numerous contract research, development, and manufacturing organizations are seeking to enhance their service offerings by merging with both small and large pharmaceutical companies, biotech firms, and many life science companies.

Moreover, market players have been focusing on initiatives to expand their presence in key regions.

• For instance, in February 2025, Novotech partnered with Wonju Severance Christian Hospital to strengthen clinical trial capabilities in South Korea.

Other Trends

• Increased Outsourcing by Life Science Companies Across the Value Chain

Pharmaceutical companies, including Big Pharma and biotech startups, increasingly outsource to reduce time-to-market, mitigate risk, and cut capital investment costs. This trend is particularly strong in biologics, biosimilars, and personalized medicines.

• Rise of End-to-End Service Providers

CRDMOs offering integrated services (from discovery through commercialization) are preferred. These one-stop solutions streamline regulatory processes and reduce transfer-related delays.

• Increasing Digitalization & Smart Manufacturing

AI, machine learning, digital twins, and process automation are revolutionizing the CRDMO landscape. These technologies optimize production and enhance real-time decision-making.

• Increasing Adoption of Green & Sustainable Manufacturing

CRDMOs are adopting green chemistry, energy-efficient equipment, and zero-waste goals in response to regulatory and societal pressures.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Increasing Outsourcing of Clinical Trials and Medicines Production to Fuel Market Growth

The market has grown significantly in the past few years, driven by the outsourcing of clinical trials and manufacturing processes. It allows pharmaceutical companies to reduce operational costs. By leveraging CRDMOs' expertise and resources, companies can avoid heavy investments in infrastructure and personnel.

Moreover, CRDMOs often have specialized knowledge and cutting-edge technology that may not be available to pharma and biotech companies within their in-house facilities. This access can be crucial for the successful development and manufacturing of complex drugs, especially biologics and advanced therapies. The rising partnerships among CRDMOs and pharmaceutical companies are boosting market growth.

Furthermore, the surging strategic collaborations among pharma companies and CRDMOs for a wide range of services, including clinical trial material manufacturing, regulatory support, and, in some cases, full clinical trial execution, enable them to support the entire drug development process from research to commercialization, boosting the global contract research, development, and manufacturing organization (CRDMO) market growth.

• For instance, in May 2024, Boehringer Ingelheim International GmbH signed a strategic agreement with Quallent Pharmaceuticals to help expand patient access to citrate-free adalimumab-adbm.

MARKET RESTRAINTS

Stringent Regulatory Scenarios in Different Regions May Restrict Market Growth

The market has experienced significant growth due to increasing demand for outsourced pharmaceutical development and manufacturing services. However, stringent regulatory scenarios can pose challenges that limit the growth and operational flexibility of CRDMOs.

The CRDMOs must ensure that their facilities and processes comply with GMP standards set by regulatory bodies such as the U.S. FDA (Food and Drug Administration) and EMA (European Medicines Agency). These regulations require rigorous documentation, validation, and quality control processes. Failure to comply can lead to fines, product recalls, or even facility shutdowns.

Additionally, the approval of new drugs or biologics often requires extensive clinical trials and documentation, which can delay CRDMO timelines. For instance, if a pharmaceutical company partners with a CRDMO to develop a new biologic, the CRDMO must navigate complex regulatory pathways, including Investigational New Drug (IND) applications and New Drug Applications (NDAs). Any delays in these processes can adversely affect the CRDMO's operational timelines and revenue.

• For instance, in June 2024, AbbVie announced that it had received a Complete Response Letter (CRL) from the U.S. FDA (Food and Drug Administration) regarding its New Drug Application (NDA) for ABBV-951 (foscarbidopa) for the treatment of motor fluctuations in advanced Parkinson's disease. The CRL from the FDA did not identify any issues with ABBV-951 itself but rather with the third-party manufacturer.

MARKET OPPORTUNITIES

Rising Drug Development & Manufacturing Costs Coupled with Collaborations to Create Lucrative Opportunities

Over the past few years, the pharmaceutical industry has been facing several external challenges, including rapidly growing global demand, changing product landscapes, supply chain pressures, inflation, and workforce shortages. These challenges are driving up drug development and manufacturing costs for pharmaceutical and biotechnological companies.

The development and manufacturing of several drugs require specialized equipment, materials, testing equipment, and reagents, which can be expensive for some pharmaceutical firms. This is expected to shift these companies toward contract research, development, and manufacturing organizations (CRDMOs) that specialize in complex drug development and manufacturing processes.

• For instance, as of May 2026, Amber Lifesciences, in partnership with CRDMOs, ensures the efficient production of its pharmaceutical

MARKET CHALLENGES

Fragmented Market and Presence of Various Small and Mid-sized Companies Act as a Challenge for Market Players' Growth

The global contract, research, development, and manufacturing and organization (CRDMO) market is highly fragmented, with many small and mid-sized companies. Moreover, the emergence of many start-ups offering similar products has been fueling market competition.

Talent and Skill Shortage to Create Challenges for Industry Expansion

As the demand for complex biologics and cell therapies grows, there is a shortage of qualified professionals in process development, quality, and regulatory compliance. This is anticipated to pose a major challenge in fulfilling requirements by pharmaceutical firms, limiting CRDMOs' growth upto certain extent.

Segmentation Analysis

By Service

To know how our report can help streamline your business, Speak to Analyst

CMO Segment led the Market Owing to Increasing Partnerships between Life Sciences Companies and CMOs

Based on service, the market is divided into CMO and CRO. The CMO segment is further categorized into API manufacturing, finished product manufacturing, and packaging. Moreover, the finished product manufacturing segment is further divided into solid dosage forms, injectables, and others.

On the other hand, the CRO segment is divided into early phase development services, clinical, laboratory service, and others. The early phase development services segment is further categorized into chemistry, manufacturing, and controls (CMC), preclinical service, and discovery. Moreover, the clinical segment is sub-segmented into phase 1, phase 2, phase 3, and phase 4.

The CMO segment dominated the global contract research, development, and manufacturing organization (CRDMO) market share in 2025. The segment growth is attributed to the surging strategic partnerships among CRDMOs and pharmaceutical/biotechnological companies for the research, development, and manufacturing of novel therapeutics.

• For instance, in August 2025, IQVIA Inc. collaborated with Flagship Pioneering to accelerate the development of life sciences companies. The collaboration spans drug development strategy, clinical development, and analytics services aligned with CRO and R&D operations.

On the other hand, the CRO segment is expected to grow at a CAGR of 9.0% during the forecast period.

Contract Research, Development, and Manufacturing Organization (CRDMO) Market Regional Outlook

Based on region, the market is studied across North America, Europe, Asia Pacific, and the rest of the world.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the largest market share in 2024 by generating a revenue of USD 93.16 billion, and in 2025, the regional value stood at USD 99.89 billion.  The region is anticipated to hold a leading position in the market over the forecast period mainly due to the presence of well-established CRDMOs. Moreover, there are a large number of clinical trials conducted in the U.S., which is an additional factor in favor of CRDMO services.

• For instance, according to data from the World Health Organization (WHO), 197,090 clinical trials were conducted in 2025.

U.S. Contract Research, Development, and Manufacturing Organization (CRDMO) Market

In 2026, the U.S. is projected to reach USD 98.49 billion, accounting for approximately 35.0% of the global market.

Europe

The Europe market is projected to record a CAGR of 8.4% during the projection period, the third highest globally, reaching USD 70.69 billion by 2026. The market growth in the region is attributed to the increasing focus of market players on participating in medical conferences to raise awareness of their contract research, development, and manufacturing services in the European market, which is one of the main factors boosting regional market growth.

• For example, in March 2025, Scinai Immunotherapeutics Ltd., a biopharmaceutical company specializing in Inflammation and Immunology (I&I) biological products and in providing CRDMO services through its Scinai Bioservices unit. The company showcased its innovative I&I product pipeline in partnership meetings and exhibited its CRDMO boutique services at the BIO-Europe Spring 2025 conference, which took place from March 17 to 19 in Milan, Italy.

U.K. Contract Research, Development, and Manufacturing Organization (CRDMO) Market

The U.K. market is expected to reach USD 13.28 billion by 2026, accounting for roughly 4.7% of global revenues.

Germany Contract Research, Development, and Manufacturing Organization (CRDMO) Market

The Germany market is projected to reach USD 17.57 billion by 2026, accounting for approximately 6.2% of global revenue.

Asia Pacific

By 2026, the Asia market is expected to reach USD 71.74 billion, ranking second globally. The increasing focus of pharmaceutical companies on expanding R&D investment and the rising demand for effective therapeutics for chronic diseases are among the factors driving the market growth in the region.

Japan Contract Research, Development, and Manufacturing Organization (CRDMO) Market

The Japan market is projected to generate USD 12.66 billion in revenue by 2026, accounting for approximately 4.5% of the global market.

China Contract Research, Development, and Manufacturing Organization (CRDMO) Market

The China market is expected to reach nearly USD 21.01 billion by 2026, accounting for 7.5% of global revenues.

India Contract Research, Development, and Manufacturing Organization (CRDMO) Market

The India market is projected to reach USD 18.03 billion by 2026, accounting for around 6.4% of global market revenue.

Rest of the World

The rest of the world is expected to grow moderately, with the market size anticipated to reach USD 31.40 billion by 2026. The market growth in the region is driven by the increasing preference of market players to conduct clinical trials, given the region's cost-effectiveness compared to other developed countries.

COMPETITIVE LANDSCAPE

KEY INDUSTRY PLAYERS

Focus of Market Players on Strategic Partnerships to Enhance Product Offerings is Responsible for Revenue Growth

The global contract research, development, and manufacturing organization market is led by key companies such as WuXi AppTec, Pharmaron, and Curia Global, which accounted for major market share in 2025. These players have been focusing on strategic partnerships to enhance their service offerings.

In addition, some prominent companies operating in the global market include Thermo Fisher Scientific Inc. and others, which are focusing on various strategic developments, such as expanding services in emerging countries by establishing new facilities and acquiring small-scale service providers.

LIST OF KEY CONTRACT RESEARCH, DEVELOPMENT, AND MANUFACTURING ORGANIZATION (CRDMO) COMPANIES PROFILED

• Curia Global, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• WuXi AppTec (China)
• Pharmaron (China)
• Syngene International Limited (India)
• Aragen Life Sciences Ltd. (India)
• Symeres (Netherlands)
• Anthem Biosciences (India)
• BioDuro (U.S.)
• Quotient Sciences (U.K.)

KEY INDUSTRY DEVELOPMENTS

• April 2026: Aurigene Pharmaceutical Services announced a USD 100.0 million investment to expand CRDMO infrastructure.
• April 2026: BioDuro entered a strategic partnership with CTI Biotechnology to build an integrated platform from drug discovery to IND submission for global clients.
• March 2026: Curia Global, Inc. expanded Glasgow manufacturing capacity and enhanced its cell line development platform, expanding its services in the U.K.
• February 2026: Quotient Sciences extended its commercial manufacturing partnership with Ipsen to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP).
• January 2026: Syngene International extended long-term strategic collaboration with Bristol Myers Squibb through 2035 for drug discovery and development lifecycle.
• October 2025: Sai Life Sciences broke ground on a new 100,000 sq. ft. CMC Process R&D Center at its Hyderabad campus, scheduled for completion by September 2026.
• October 2025: Pharmaron entered a definitive agreement to acquire an 82.54% equity stake in China-based structural biology CRO Biortus Biosciences to strengthen its global protein science and structure-based drug discovery capabilities.
• September 2025: Symeres, a global CRDMO, acquired Netherlands-based regulatory consultancy DGr Pharma to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients.

REPORT COVERAGE

The global contract research, development, and manufacturing organization (CRDMO) market report provides an in-depth analysis of the industry. It provides a global market forecast based on current market dynamics and the latest market trends. In addition, the report consists of several factors that have contributed to the market growth. The report also provides the competitive landscape of the market.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation